The Best Treatment for High-Risk Myelodysplastic Syndromes – ASH
The American Society of Hematology (ASH) shared a post on X about a recent article by Sudipto Mukherjee at al. published in Blood Neoplasia:
“Hypomethylating agents are the best treatment for high-risk MDS, yet they’re underused.
A study shows many eligible patients don’t receive them or stop early, especially female and non-white patients.”
Title: Disparities in Real-World Treatment Patterns of Hypomethylating Agents Among Patients with Myelodysplastic Syndromes in the US
Authors: Sudipto Mukherjee, Weichuan Dong, Aaron T. Gerds, Hetty E. Carraway, Abhay Singh, Anjali S. Advani, Moaath K. Mustafa Ali, John Molina J, Sophia Balderman, Akriti Jain, Paolo Caimi, Faiz Anwer, Mikkael A. Sekeres, Siran M. Koroukian
Read the Full Artcle on Blood Neoplasia
More posts featuring American Society of Hematology.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023